# Jiangsu Famous Medical Technology Co. trials: 20 (2026)

ClinicalTrials.gov lists 20 trials with Jiangsu Famous Medical Technology Co., Ltd. as lead sponsor, 6 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Jiangsu Famous Medical Technology Co., Ltd.: 20 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/jiangsu-famous-medical-technology-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 2, 2026 | NCT07854405 | A Clinical Study on the Synergistic Effects of Zhen-Qi-Jie-Du Granules in Palliative Care for Advanced Colorectal Cancer | Jiangsu Famous Medical Technology Co., Ltd. | Not applicable | Not yet recruiting | Colorectal Cancer | 1,540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854405) |
| August 19, 2025 | NCT07129499 | Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas | Jiangsu Famous Medical Technology Co., Ltd. | Not applicable | Not yet recruiting | Colorectal Adenoma, High Risk, TCM | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07129499) |
| August 14, 2025 | NCT07123116 | Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas | Jiangsu Famous Medical Technology Co., Ltd. | Not applicable | Not yet recruiting | Colorectal Adenoma, TCM, Low Risk | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123116) |
| September 25, 2024 | NCT06613373 | An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 | Unknown | Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06613373) |
| August 5, 2024 | NCT06537674 | Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer | Jiangsu Famous Medical Technology Co., Ltd. | Observational | Not yet recruiting | HER2+ Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06537674) |
| November 18, 2023 | NCT06136026 | Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer | Jiangsu Famous Medical Technology Co., Ltd. | Observational | Not yet recruiting | Colorectal Cancer, Colorectal Adenoma | 50,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06136026) |
| February 2, 2023 | NCT05709249 | Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer | Jiangsu Famous Medical Technology Co., Ltd. | Phase 3 | Recruiting | Colon Cancer | 730 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05709249) |
| August 1, 2022 | NCT05482009 | Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine | Jiangsu Famous Medical Technology Co., Ltd. | Observational | Completed | Angina Pectoris | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05482009) |
| March 31, 2022 | NCT05305456 | Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19 | Jiangsu Famous Medical Technology Co., Ltd. | Phase 3 | Completed | Novel Coronavirus Pneumonia | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05305456) |
| March 23, 2021 | NCT04812236 | Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 | Unknown | Metabolic Syndrome | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04812236) |
| August 12, 2020 | NCT04509323 | Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 | Unknown | Neurosensory Disorder | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04509323) |
| March 13, 2020 | NCT04306497 | TCM Differentiation and Treatment Protocol of COVID-19 | Jiangsu Famous Medical Technology Co., Ltd. | Observational | Completed | COVID-19 | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04306497) |
| February 10, 2020 | NCT04261920 | Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 | Unknown | Oncology | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04261920) |
| May 9, 2019 | NCT03943420 | One Research on Improving Cognitive Impairment Caused by Hypertension | Jiangsu Famous Medical Technology Co., Ltd. | Observational | Unknown | Hypertension | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03943420) |
| August 6, 2018 | NCT03616444 | A Randomized Clinical Trial of Shenbai Granules in Reducing Recurrence of Colorectal Adenoma | Jiangsu Famous Medical Technology Co., Ltd. | Phase 2/3 | Completed | Gastroenterology | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03616444) |
| August 29, 2017 | NCT03264794 | the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 | Unknown | Non-small Cell Lung Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03264794) |
| January 13, 2017 | NCT03020940 | The Clinical Trial of Cefuroxime Axetil Dispersible Tablets | Jiangsu Famous Medical Technology Co., Ltd. | Observational | Unknown | Infectious Disease | 100,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03020940) |
| January 13, 2017 | NCT03020901 | the Clinical Trial of Teicoplanin for Injection | Jiangsu Famous Medical Technology Co., Ltd. | Observational | Unknown | Infectious Disease | 100,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03020901) |
| January 11, 2017 | NCT03016832 | Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease | Jiangsu Famous Medical Technology Co., Ltd. | Early phase 1 | Unknown | Diabetic Kidney Disease | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03016832) |
| December 15, 2016 | NCT02993419 | Bacillus Particles Prevent Children Antibiotics Associated Diarrhea | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 | Unknown | Antibiotic-associated Diarrhea | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02993419) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 6 |
| Not applicable | 3 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 10 |
| Not yet recruiting | 5 |
| Completed | 4 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Communicable Diseases | 2 |
| Colorectal Neoplasms | 2 |
| Colonic Neoplasms | 1 |
| Neoplasms | 1 |
| COVID-19 | 1 |
| Breast Neoplasms | 1 |
| Hypertension | 1 |
| Cognitive Dysfunction | 1 |
| Sensation Disorders | 1 |
| Diabetic Nephropathies | 1 |
| Angina Pectoris | 1 |
| Lymphoma, Follicular | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Metabolic Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
- [Falafel restaurants in the United States](https://specstream.ai/data/businesses/falafel-restaurants/united-states)
- [Malaysian restaurants in the United States](https://specstream.ai/data/businesses/malaysian-restaurants/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
